Dan
Founder, Blueshot
Founder of Blueshot. Writes GLP-1 medication guides grounded in primary clinical sources (NEJM, JAMA, FDA labels) and real Korean/US pricing.
Articles
Medication GuideGLP-1 Nausea, Bloating, and Sulfur Burps: What Helps and When to Worry
Nausea hits 44% on Wegovy and 33% on Mounjaro. Sulfur burps, constipation, and bloating follow close behind. A meal-by-meal, hour-by-hour playbook for the rough days.
Medication GuideGLP-1 Summer Travel Storage: Drug-by-Drug Cold Chain Guide (2026)
Car trunks hit 70°C in 30 minutes. Mounjaro's out-of-fridge window is just 21 days. Drug-by-drug packing plan for summer flights and road trips.
Medication GuideOzempic vs Wegovy: Same Drug, Different Rules
Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide. So why do they cost different amounts, and which one should you ask about?
Medication GuideSwitching GLP-1 Meds: Dose Maps and Real Talk
Thinking about switching from Wegovy to Mounjaro — or from injections to the new pill? Here's how dose mapping actually works and what the transition feels like.
Medication GuideGLP-1 and Bone Loss: What Rapid Weight Loss Does to Your Skeleton (2026)
Lose 15% of your body weight and you'll lose some bone too. DXA data from STEP and SURMOUNT show how much — and what actually protects you.
NewsGLP-1 Drugs Just Became the World's Best-Selling Drug Class (2026)
Novo Nordisk and Eli Lilly's GLP-1 revenue hit $60B+ annualized in Q1 2026, overtaking oncology. What record sales mean for pricing, supply, and access.
Medication GuideGLP-1 and Pancreatitis: Separating Real Risk from Internet Panic (2026)
Pancreatitis is on every GLP-1 label. Clinical trial rates are under 0.5%. Here's what STEP, SURMOUNT, and SELECT actually show.
Medication GuideGLP-1 and Thyroid Cancer: What the Black Box Warning Actually Means (2026)
Every GLP-1 drug carries a boxed warning about thyroid cancer. But 145,000-patient cohort data and 15 years of surveillance say the human risk is near zero. Here's the evidence.
Medication GuideGLP-1 and Gallbladder Problems: What the Data Actually Shows (2026)
Gallstones and cholecystitis are a real risk on semaglutide and tirzepatide — about 2–3% in trials vs 1% on placebo. Here's why it happens, who's most at risk, and what to watch for.
Medication GuideYour Stomach on a GLP-1: Gastroparesis, Nausea, and What the Evidence Actually Says
Gastroparesis fears, sulfur burps, nausea that makes you question everything — here's what the clinical data says about GLP-1s and your gut, and when to worry.
Medication GuideGLP-1 Long-Term Safety: What the Trial Data Shows (2026)
LEADER, REWIND, SELECT, SOUL, FLOW — 50,000+ patients, up to 5.4 years. What the long-term data says about thyroid, heart, kidneys, gallbladder, and more.
Medication GuideEvery Pill You Take With a GLP-1 — What Actually Interacts and What Doesn't
You're on Wegovy or Mounjaro and you take other meds too. Here's what the prescribing labels, clinical data, and your pharmacist actually worry about.
Medication GuideGLP-1 Weight Loss Plateau: Why You Stalled and What Actually Works
Most people hit a wall at months 3-6 on semaglutide or tirzepatide. The plateau isn't failure — it's biology. Here's what the STEP and SURMOUNT data says about breaking through.
Medication GuideYour Kidneys on GLP-1: What the FLOW Trial Found (and What It Means for You)
The FLOW trial stopped early because semaglutide cut major kidney events by 24%. If you have type 2 diabetes and CKD, here's what the 2024 data means for your kidneys.
NewsOral Semaglutide Hits 400K Users — Where the GLP-1 Pill Stands Globally
Four months after US launch, oral semaglutide for obesity has 400,000 patients on it. Here's which markets have it, which are next, and what the real-world data says so far.
NewsYour Liver Might Already Be Getting Better — GLP-1 and Fatty Liver Disease
If you're on a GLP-1 for weight loss, the ESSENCE and SYNERGY-NASH trials suggest your liver may be healing too. Here's what the 2024-2025 data actually shows.
NewsGLP-1 Failed the Alzheimer's Trial — But the Brain Story Isn't Over
Semaglutide failed the EVOKE+ Alzheimer's trial. Yet observational data still shows 40-70% lower dementia risk. Prevention and treatment are different questions.
Medication GuideYour Mood on GLP-1: What the Evidence Says About Depression, Anxiety, and 'Food Noise'
GLP-1 drugs changed how millions eat. Do they also change how you feel? Here's what clinical trials, brain science, and 2 million patient records actually show.
Medication GuideGLP-1 Drugs and Cancer Risk: What the 2026 Evidence Actually Shows
A 281,656-person study found GLP-1 users had 36% lower colorectal cancer risk than aspirin users. JAMA Oncology data adds 17% lower overall cancer risk across 14 types. Here's what the evidence means for you.
Medication GuideGLP-1 cost in 2026: insurance, cash price, and every path to coverage
Wegovy lists at $1,349. Zepbound at $1,059. Medicare covers both in July for $50. Every payment path — insurance, cash, coupons, and PA denial appeals.
Medication GuideGLP-1 Hair Loss in 2026: Why Month 4 Is the Shower-Drain Moment, and What Actually Helps
STEP 1 said 3.0%. SURMOUNT-1 said 5.7%. The mechanism is telogen effluvium, the timing is month 3 to 5, and the fix is not biotin gummies.
Medication GuideGLP-1 and Pregnancy in 2026: Washout Windows, the Pill Trap, and What OB-GYNs Now Say
Washout windows by molecule, the oral-contraceptive failure your prescriber probably didn't mention, and what regulators say in 2026.
Medication GuideGLP-1 and surgery: when to pause Wegovy, Zepbound, and Ozempic
When to hold Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Trulicity, and Foundayo before anesthesia — exact pause windows, brand-by-market, and what to ask your team.
NewsCounterfeit Wegovy and Ozempic: How to Tell If Yours Is Real in 2026
Since 2023, the FDA, WHO, MHRA and a dozen national agencies have flagged fake Wegovy, Ozempic and Mounjaro. Here is how to verify the box in your hand.
Medication GuideWho qualifies for a GLP-1 in 2026: BMI, PA, and the Foundayo shift
The US gate is BMI 30 — or 27 with a comorbidity. Here's how that plays out at your PA, and why eight other countries draw the line elsewhere.
Medication GuideGLP-1 Protein Targets: How Many Grams You Actually Need in 2026
On Wegovy, Zepbound, Mounjaro, or Foundayo, 1.2–1.6 g/kg of protein daily is the number that separates fat loss from muscle loss. Here is how to hit it.
Medication GuideGLP-1 and Alcohol in 2026: Why One Drink Hits Like Four
Wegovy, Zepbound, Mounjaro, Ozempic plus a glass of wine — what the 2025 JAMA trial and BMJ registry data actually say, and the practical guardrails nobody hands you.
Medication GuideGLP-1 Self-Injection at Home: The 2026 Pen Playbook
Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda — how the weekly shot really goes, site by site, click by click, without wasting a $1,349 dose.
Weight ManagementGLP-1 Workout Plan: Lift, Walk, Keep the Muscle
A concrete weekly training plan for Wegovy, Zepbound, Mounjaro, Saxenda, and Foundayo users who want to lose fat without losing the strength underneath.
Weight ManagementOzempic face: why your cheeks deflate on Zepbound in 2026
Nine months into Zepbound, 42 lb down, and the mirror looks 10 years older. What the data says about Ozempic face — and the 6-month rule.
NewsZepbound for Sleep Apnea: The May 2026 Playbook
On July 1, 2026, Medicare opens Zepbound at $50/mo for SURMOUNT-OSA-qualifying beneficiaries. Here's what to do between now and then.
NewsThe US GLP-1 Rules Changed Again — What $39 Actually Buys You
March 2026: Novo and Hims restarted the deal at $39 for month one, $199 after. Here's what US shoppers actually get, and what it signals for everyone else.
User StoriesYour First Month on a GLP-1, Week by Week (2026)
Week one through week four on Wegovy or Zepbound — starting dose, the side-effect peak at day 3 to 5, food noise, and the month-one plateau that isn't one.
Medication GuideRybelsus and the SOUL Trial: An Oral GLP-1 Now Has a Heart Indication
SOUL is the first cardiovascular outcomes trial of an oral GLP-1. Rybelsus cut 3-point MACE 14% in T2D patients with established heart or kidney disease.
NewsMedicare's $50 Wegovy Lands July 1 — and Seoul, Tokyo and Dubai Feel It
July 1, 2026: 67 million Medicare enrollees get Wegovy and Zepbound for $50 a month. The ripple lands in Seoul, Tokyo, Berlin, Dubai and Taipei before Labor Day.
NewsGLP-1 and Addiction: What the March 2026 BMJ Study Actually Shows
A March 2026 BMJ study of 600,000+ US veterans ties GLP-1 drugs to lower new-onset addiction rates and fewer overdose deaths. Read it carefully.
Medication GuideMounjaro side effects in 2026: what's expected, what's a red flag
Nausea and reflux are common on tirzepatide. Sudden severe belly pain or a new neck lump are not. The SURMOUNT-1 numbers and what changed in 2026.
NewsThe Next Wave of Obesity Drugs: What's Actually Coming After Wegovy and Zepbound
CagriSema, retatrutide, amycretin, survodutide, MariTide — five late-stage obesity drugs and what each country's patients will see first as of April 2026.
Weight ManagementWhat to eat on Wegovy, Zepbound, and Foundayo in 2026
Protein target, nausea-safe foods, and a US grocery-aisle playbook for eating well on Wegovy, Zepbound, Mounjaro, Saxenda, and Foundayo.
Medication GuideSemaglutide vs. Tirzepatide in 2026: Same Two Molecules, Nine Different Pharmacies
Wegovy and Zepbound in the US. The same two molecules under different brand names in nine markets. SURMOUNT-5 put the head-to-head at −20.2% vs −13.7%.
Medication GuideHow much muscle are you losing on GLP-1? 2026 trial data
STEP 1 says about 40% of the weight lost on semaglutide is lean mass. SURMOUNT-1 says closer to 25%. Here is what that means.
Medication GuideMounjaro and Zepbound Dose Titration Schedule 2026
Tirzepatide climbs 2.5 mg to 15 mg on a fixed weekly ladder. The dose-by-dose Mounjaro and Zepbound schedule, and when holding beats pushing.
Medication GuideGeneric Saxenda in Korea: What the Liraglutide Copy Story Actually Means in 2026
The FDA cleared generic liraglutide in Dec 2024 and Biocon's gSaxenda in Feb 2026. Korea signed the deal — but 'approved' is not 'cheaper this month'.
Medication GuideStopping Wegovy or Zepbound: What the Trial Data Actually Shows About the Rebound
Hunger comes back in weeks. Weight comes back in months. The trial numbers on regain are less reassuring than most prescribers admit, so here is what the record shows.
Medication GuideMounjaro and Zepbound Cost in the US 2026: What You Really Pay
Tirzepatide is sold as two US brands — Mounjaro for type 2 diabetes, Zepbound for obesity. Here is what the April 2026 price lanes, PBM reality, and Lilly Self Pay vials add up to.
NewsAfter the GLP-1 crackdown: what U.S. patients do next
After the FDA cracked down on compounded semaglutide and tirzepatide, U.S. patients are making different choices about Wegovy, Zepbound, and the next refill.
Medication GuideWeight loss drugs 2026: which ones are actually approved in the U.S.?
If you search weight loss drugs 2026, the U.S. list looks bigger than it is. Here's the cleaner split between FDA-approved brands, what's sold, and what plans may cover.
Medication GuideAre Zepbound and Mounjaro the same drug? Same tirzepatide, different U.S. labels
Same tirzepatide, same dosing ladder. But in the U.S., Zepbound is the obesity brand and Mounjaro is the diabetes brand — and that changes coverage and cost.
Medication GuideWegovy side effects in 2026: what's normal, what's not
Nausea is common. Sudden severe belly pain or vision loss is not. What Wegovy side effects usually feel like, which are red flags, and what FDA/EMA changed.
Medication GuideWegovy Pill vs. Wegovy Shot in 2026: Cost, Dosing, Weight Loss, and Where Zepbound Fits
Oral Wegovy is a real daily tablet in the U.S. Different price ladder, dosing, and switching logic from the weekly shot. Clean 2026 comparison.
Medication GuideWegovy vs. Zepbound: Which One Makes More Sense in 2026?
US-first comparison of Wegovy and Zepbound: weight-loss data, side effects, coverage, cost, and the practical differences past the headline percentages.
NewsFoundayo in 2026: the new GLP-1 pill that skips fasting rules
Foundayo got FDA approval on April 1, 2026. A once-daily oral GLP-1 — no food or water restrictions. Here is what the label and ATTAIN trials actually say.
Medication GuideHow Much Wegovy Costs in Korea in 2026
In Korea, Wegovy has no single monthly price. The real number depends on dose, clinic fees, and treatment length. The cleanest way to budget in 2026.